Latest Breaking News On - Research business development - Page 6 : vimarsana.com

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

04.03.2022 - NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and .

Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as President Life Science

Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as President Life Science - read this article along with other careers information, tips and advice on BioSpace

Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as President Life Science

/PRNewswire/ Getinge appoints new Presidents for two business areas and members of the Executive team. Elin Frostehav is appointed President Acute Care.

Annual Faculty Synergy Research Event celebrates collaboration and achievements

Sharing ideas that facilitate the discovery of answers to important questions can be an essential part of scientific research. On Tuesday, Dec.

ANU centre to turbo-charge crop production | PressReleasePoint

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease

SKKU: SKKU Ranks 1st among Private Universities in Asia University Ranking 2021

Sungkyunkwan University (SKKU) ranked 14th in Asia in the “2020 THE Asia University Rankings” released by the British global university evaluation agency, Times Higher Education (THE) on June 2 (Wed), 2021. SKKU maintained the top 3 in Korea this yea

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development

Published: May 05, 2021 NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) Anavex Life Sciences Corp.  . (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senior Vice President for Nonclinical Development. Dr. Laniyonu has over 24 years’ experience with the US Food and Drug Administration (FDA). “Dr. Laniyonu has an accomplished track record of working within the FDA,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “His depth of experience makes him an excellent choice to provide objective perspective and manage the continuous nonclinical projects at Anavex.”

MIL-OSI Africa: Vertiv Accelerates Global Channel Growth with New Investments in People, Tools, Programs and Partner Relationship Management System

Source: Africa Press Organisation – English – Report: Vertiv Accelerates Global Channel Growth with New Investments in People, Tools, Programs and Partner Relationship Management System New strategies focus on streamlining interactions and increasing profitability for partners DUBAI, United Arab Emirates, March 9, 2021/APO Group/ Vertiv, (NYSE: VRT) (www.Vertiv.com/en-emea), a global provider of critical digital infrastructure and continuity solutions, today announced additions and enhancements to the Vertiv Partner Program (https://bit.ly/30okRmr) to expand access to IT decision makers and enrich the Vertiv experience for partners and customers. The investment in the Partner Program includes new global channel oversight and a new global partner relationship management system that allows partners to interface with Vertiv for deal registrations, configuration tools and anything they might need to initiate, manage or complete work with Vertiv. These improvements are part of Vert